{"filings":[{"id":2163037,"accession_number":"0001193125-26-342463","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2026-08-10T20:27:00+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q2 revenue up 33% to $28.1M; raises FY2026 guidance to $114-117M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $28.1M, up 33% YoY; product revenue $21.2M, subscription $6.9M.","Net loss $19.3M ($0.51/share) vs $13.6M loss YoY; adjusted EBITDA loss $9.8M.","Gross margin 92% (up from 88%) on cost cuts, Vietnam line, and tariff refunds.","New $60M credit facility (term loan + revolver) refinances debt; cash $129.3M.","Raised FY2026 revenue guidance to $114-117M (28-31% growth); FDA clearances for algorithms and hardware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1949367,"accession_number":"0001193125-26-324378","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2026-07-29T23:00:50+00:00","items":["5.02"],"status":"ready","headline":"CeriBell adds two new directors, rebalances board classes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 7 to 9; Sharon L. O'Keefe and Thomas A. West elected as Class I directors.","William W. Burke moved from Class I to Class II; Joseph M. Taylor from Class I to Class III.","O'Keefe joins Compensation Committee; West joins Audit Committee.","Each new director receives initial RSU award valued at $300,000, vesting over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":806356,"accession_number":"0001193125-26-253558","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2026-06-02T20:19:11+00:00","items":["5.07"],"status":"ready","headline":"CeriBell stockholders elect Parvizi and Robertson as Class II directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At June 2, 2026 annual meeting, Josef Parvizi, M.D., Ph.D. elected with 25,961,193 votes for, 2,311,420 withheld, 4,374,728 broker non-votes.","Rebecca Robertson elected as Class II director with 25,948,634 for, 2,323,979 withheld, 4,374,728 broker non-votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY 2026 approved: 32,623,328 for, 5,177 against, 18,836 abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13322,"accession_number":"0001193125-26-216821","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2026-05-11T20:16:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q1 revenue $26.5M (+29% YoY); raises FY2026 guidance to $112-116M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.5M, up 29% YoY; product $20.2M, subscription $6.3M, both +29%.","Net loss $19.7M ($0.52/sh) vs $12.8M ($0.36) YoY; adj. EBITDA loss $11.2M.","Launched neonate/pediatric EEG products; 680 active accounts at quarter end.","CMS proposed rule for NTAP reimbursement for delirium monitoring; final rule Aug 2026.","FY2026 revenue guidance raised to $112-116M (26-30% growth); cash $141.2M."],"consensus_eps_estimate":-0.3978,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":26494000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110185,"accession_number":"0001193125-26-067136","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q4 revenue $24.8M (+34% YoY); FY 2026 guidance $111-115M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $89.1M (+36% YoY); net loss $53.4M ($1.46/share).","Q4 gross margin 87%; active accounts 647; cash $159.3M.","FY 2026 revenue guidance $111-115M, representing 25-29% growth.","FDA 510(k) clearance for continuous delirium monitoring and neonatal seizure detection.","FDA Breakthrough Device Designation for large vessel occlusion stroke detection solution."],"consensus_eps_estimate":-0.4206,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":89063000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110184,"accession_number":"0001193125-26-001800","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ceribell receives FDA Breakthrough Device Designation for LVO stroke detection system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Breakthrough Device Designation granted for CeriBell's LVO stroke detection and monitoring solution.","First-in-class point-of-care EEG technology using existing hardware and AI algorithm to interpret signals.","Nearly 800,000 annual US strokes; LVO strokes cause 62% of post-stroke dependence and 96% of mortalities.","Designation supports potential expedited development; follows recent 510(k) clearances for Clarity and delirium screening.","Targets in-hospital stroke patients, where detection and treatment delays lead to 3x higher mortality."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110183,"accession_number":"0001193125-26-000994","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CeriBell director Lucian Iancovici resigns from Board, effective Dec. 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lucian Iancovici resigned from CeriBell Board and committee roles, effective Dec. 31, 2025.","Resignation is for personal focus on other professional ventures; no disagreement with company.","Iancovici served as Chair of Nominating and Corporate Governance Committee and Compensation Committee member.","He acknowledges no outstanding claims and releases company from potential liabilities.","Company states resignation not due to any disagreement on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126746,"accession_number":"0001193125-25-317295","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ceribell extends two Sunnyvale CA leases to Jan 2028; monthly rent ~$109k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["625 N. Pastoria lease extended one year to Jan 2028; monthly rent $34,821.","360 N. Pastoria lease extended to Jan 2028; monthly rent $74,147.","Combined monthly rent for both leases approx $108,968.","Both amendments executed Dec 11, 2025; effective Dec 4 & Dec 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126745,"accession_number":"0001193125-25-312035","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ceribell receives FDA 510(k) clearance for first delirium monitoring solution","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Ceribell's EEG-based delirium screening and monitoring system for critically ill patients.","Algorithm validated in prospective study of 225 adults in critical care; continuous monitoring at bedside.","Delirium affects ~31% of ICU patients and up to 80% of mechanically ventilated; associated with higher mortality and dementia risk.","Ceribell has submitted NTAP application to CMS for the new indication; leverages existing commercial footprint.","CEO Jane Chao expects to finalize go-to-market strategy soon; builds on prior Breakthrough Device Designation (2022)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126744,"accession_number":"0001193125-25-292140","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ceribell receives FDA 510(k) clearance for Clarity algorithm to detect seizures in neonates","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clearance covers use of Clarity algorithm for electrographic seizure detection in newborns preterm and older through adults, the first AI-powered point-of-care EEG for all ages.","Clearance supported by EEG data from over 700 patients, the largest known validation dataset for a neonatal seizure detection system.","Approximately 9% of NICU patients may have seizures, but up to 90% go undetected without EEG monitoring, per the release.","Ceribell previously received 510(k) clearance for a headcap optimized for the neonatal population.","CEO Jane Chao cited the clearance as expanding availability of rapid, AI-powered neurological monitoring to more patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126743,"accession_number":"0001193125-25-264699","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q3 revenue $22.6M (+31% YoY); raises FY 2025 guidance to $87-89M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $17.0M (+28%); subscription revenue $5.6M (+44%).","Gross margin 88% vs 87% a year ago; net loss $13.5M ($0.37 per share).","Total active accounts 615; cash & equivalents $168.5M.","FY 2025 revenue guidance raised to $87-89M (33-36% growth).","Appointed Erica Rogers to the Board of Directors."],"consensus_eps_estimate":-0.4218,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":64279000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143536,"accession_number":"0001193125-25-214813","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ceribell adds Vietnam manufacturing facility for headbands via Everwin Amendment No. 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 3 designates Everwin Vietnam as agent to deliver headbands from facility in Nghe An, Vietnam.","Previous Amendment No. 2 (Nov 2023) added Hong Kong agent and Tijuana, Mexico deliveries; now disclosed for first time.","Supply agreement term extended to Dec 31, 2027 under Amendment No. 2; Amendment No. 3 is valid per existing term.","No material financial terms or price adjustments disclosed in Amendment No. 3; prices redacted as confidential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143535,"accession_number":"0001193125-25-210195","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Erica Rogers appointed to Ceribell Board; former Silk Road Medical CEO brings medtech scaling expertise","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erica Rogers elected to Board effective Sept 17, 2025, and appointed to Compensation Committee.","Rogers served as CEO of Silk Road Medical, growing it from startup to $175M revenue and acquisition by Boston Scientific.","She has over 30 years of experience in high-growth medical device companies and holds multiple patents.","Ceribell's rapid EEG system is used in >550 hospitals; Rogers to help scale adoption as standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143534,"accession_number":"0000950170-25-103052","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q2 revenue $21.2M (+38% YoY); raises FY2025 guidance to $85-88M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $21.2M, up 38% YoY from $15.3M; product revenue $15.9M, subscription $5.3M.","Gross margin 88% vs 86% a year ago; net loss $13.6M ($0.38 per share) vs $8.9M loss ($1.61) prior year.","Operating expenses rose 56% to $33.6M on investments in commercial team and public company costs.","Active accounts reached 584; cash and marketable securities $177.4M as of June 30, 2025.","FY2025 revenue guidance raised to $85-88M, representing ~30-34% growth over prior year."],"consensus_eps_estimate":-0.4006,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":41690000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143533,"accession_number":"0000950170-25-094303","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CeriBell files patent infringement lawsuits against Natus Medical with USITC and Delaware court","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaints at USITC and Delaware District Court alleging infringement of six CeriBell patents.","Seeks USITC exclusion order to bar import of infringing Natus EEG products into the U.S.","Patents cover CeriBell EEG headband and electrode design used in point-of-care EEG technology.","CEO Jane Chao states CeriBell will vigorously protect its IP against infringement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161728,"accession_number":"0000950170-25-088309","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ceribell exercises option to extend Stanford license exclusivity through patent expiration for $250K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercised option on June 12, 2025 to extend exclusive license for brain wave detection devices.","Pays $250,000 exercise fee; remaining $20,000 waiver triggered.","Exclusivity now runs through expiration of the last licensed patent, removing June 2025 sunset.","No further milestone payments are due under amended agreement.","License covers four Stanford inventions from Parvizi and Chafe labs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161727,"accession_number":"0000950170-25-085227","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CeriBell shareholders elect two Class I directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Juliet Tammenoms Bakker elected with 20,199,817 votes for, 2,031,435 withheld.","Lucian Iancovici, M.D. elected with 19,009,795 votes for, 3,221,457 withheld.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2025 passed with 23,287,906 votes for.","Meeting held June 10, 2025; all proposals approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161726,"accession_number":"0000950170-25-066974","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q1 revenue $20.5M (+42% YoY); raises FY2025 guidance to $83-87M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $20.5M (+42% YoY); product $15.6M (+41%), subscription $4.9M (+45%).","Net loss $12.8M ($0.36 diluted EPS) vs $8.5M ($1.56) YoY; gross margin 88% (86% prior year).","Raised 2025 revenue guidance to $83-87M (27-33% growth over prior year).","Cash and marketable securities $182.7M; 558 active accounts at quarter end.","FDA 510(k) clearance for pediatric Clarity algorithm (ages 1+); received FedRAMP High authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":20491000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161725,"accession_number":"0000950170-25-053034","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CeriBell sees 8-10 ppt gross margin drag from 145% China tariffs after Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2024 gross margin 87%; tariffs on Chinese-sourced goods expected to reduce margin by 8-10 percentage points.","Effective tariff rate of 145% on goods from China; no material impact until Q4 2025 due to FIFO inventory accounting.","Inventory on hand as of April 11, 2025 sufficient to supply headband products through Q3 2025.","Subscription product cost of revenue not affected by tariffs.","Both contract manufacturers for headband product located in China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179825,"accession_number":"0000950170-25-039317","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CeriBell raises CEO, CFO, CTO base salaries and incentive targets effective April 1, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Xingjuan (Jane) Chao annual base salary increased to $685,000 and target annual incentive to 95% of base.","CFO Scott Blumberg base salary raised to $460,000 with target annual incentive of 50% of base.","CTO Raymond Woo base salary increased to $444,000 and target annual incentive set at 50% of base.","Changes approved by Board on March 10, 2025, effective April 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179824,"accession_number":"0000950170-25-026668","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q4 revenue $18.5M (+41% YoY); FY2024 revenue $65.4M (+45%); guides FY2025 $81-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $18.5M (+41% YoY); product $14.1M, subscription $4.4M; gross margin 88%.","FY2024 revenue $65.4M (+45%); net loss $40.5M ($3.39/share) vs $29.5M ($5.56/share) in 2023.","Cash and equivalents $194.4M at Dec 31, 2024; active accounts 529; over 200,000 patients treated.","FY2025 revenue guidance $81-85M, representing 24-30% growth over FY2024.","Submitted 510(k) for pediatric Clarity algorithm; Sean Manni promoted to Chief Revenue Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":65444000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179823,"accession_number":"0000950170-25-004633","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ceribell presents at J.P. Morgan Healthcare Conference; no financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Ceribell scheduled to present at 2025 J.P. Morgan Annual Healthcare Conference on January 13, 2025.","No specific financial results, guidance changes, or product announcements mentioned in the filing.","Presentation materials furnished but not filed; no material new information beyond conference participation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196582,"accession_number":"0000950170-24-125371","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ceribell Q3 revenue $17.2M (+48% YoY); net loss $10.4M; guides FY2024 rev $64.2-64.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $13.3M (+52%), subscription revenue $3.9M (+36%).","Gross margin improved to 87% from 84% YoY.","Net loss per share $1.85 vs $1.32 in Q3 2023.","Full-year 2024 revenue guidance $64.2-64.7M (42-43% growth).","IPO closed Oct 15, net proceeds ~$188M; cash $14.1M at Sept 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":46910000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196581,"accession_number":"0000950170-24-114767","cik":1861107,"company_name":"Ceribell, Inc.","ticker":"CBLL","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"CeriBell closes IPO of 12.2M shares at $17.00, gross proceeds ~$207.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 12,196,969 shares (including 1,590,909 overallotment shares) closed on Oct 15, 2024 at $17.00 per share.","Gross proceeds to CeriBell were approximately $207.3 million before underwriting discounts and expenses.","Amended charter and bylaws became effective, including classified board, 66 2/3% supermajority vote requirements, and exclusive forum provisions.","Common stock trades under ticker CBLL on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":709149080.9903743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}